SL Swiss Lipid Navigator
Demonstration prototype — synthetic data only, simplified rules, not for clinical use.
Step 10 of 10 · Decision support

Summary

What this step shows

All results for this patient in one view, with the reasoning behind each step. Update any value and the results are recalculated.

Sophie Berger
DEMO-4 · 55 years · Female · born 26.05.1971 · LDL-C measured 25.08.2026
Update lab values
Clinical pathwaySpecial Category — Familial Hypercholesterolemia
Risk categoryVery High
LDL-C (current)3 mmol/L
LDL-C target<1.4 mmol/L
Current treatmentNo statin + ezetimibe
Recommended next stepConsider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)
Swiss reimbursement Eligible
Reasoning by step
  1. Step 5 — Clinical pathway View details →
    Special Category — Familial Hypercholesterolemia

    Patients with (suspected) FH are handled by dedicated FH risk rules rather than the general-population calculator.

  2. Step 6 — Cardiovascular risk View details →
    Very High

    Familial hypercholesterolemia with a very high LDL-C burden (or a high baseline plus an added risk factor) is treated as Very High risk in this demo ruleset.

  3. Step 7 — LDL-C target View details →
    <1.4 mmol/L

    Very High risk → target <1.4 mmol/L (and ≥50% reduction from baseline where baseline is known).

  4. Step 8 — Treatment plan View details →
    Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)

    Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.

  5. Step 9 — Swiss reimbursement View details →
    Eligible

    All demo reimbursement criteria are met.

Demonstration output based on simplified rules — not clinical advice. Generated 02.11.2026 17:30.

← Swiss reimbursement
Back to patients →